The purpose of the study is to determine the safety of DMP 543 during multiple dosing in patients with Alzheimer's disease. Identification of a minimum intolerable dose as defined by adverse experiences will be subject to the limitation of individual peak plasma concentrations, not to exceed 5.0 ng/ml during dosing. The study will be a single-site, placebo-controlled escalating multiple dose, inpatient and outpatient study. Yale will be the only study site. Study was terminated in November 1998 by Industry Sponsor.
Showing the most recent 10 out of 343 publications